

Accepted Manuscript

Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome

L. Jeraj, M.K. Jezovnik, P. Poredos

PII: S0049-3848(17)30347-X
DOI: doi: [10.1016/j.thromres.2017.05.029](https://doi.org/10.1016/j.thromres.2017.05.029)
Reference: TR 6672
To appear in: *Thrombosis Research*
Received date: 5 January 2017
Revised date: 20 May 2017
Accepted date: 25 May 2017



Please cite this article as: L. Jeraj, M.K. Jezovnik, P. Poredos , Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome, *Thrombosis Research* (2017), doi: [10.1016/j.thromres.2017.05.029](https://doi.org/10.1016/j.thromres.2017.05.029)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome**Short title:** Rivaroxaban vs. warfarin and post-thrombotic syndrome

L Jeraj*, MK Jezovnik**, P Poredos*

*Department of vascular disease, University Medical Centre Ljubljana, Slovenia

** University of Texas, Health Science Center at Houston, Houston, Texas, USA

Corresponding author:

Prof. Pavel Poredoš, MD, PhD

Department of vascular disease, UKC Ljubljana

Zaloška cesta 7, 1000 Ljubljana, Slovenia

Phone: 00 386 41 703 038

e-mail: pavel.poredos@kclj.si

Other authors:

Luka Jeraj, MD

Assoc. Prof. Mateja Kaja Ježovnik, MD, PhD

Main body word count: 1519

Number of references: 15

Number of tables: 1

Download English Version:

<https://daneshyari.com/en/article/5621916>

Download Persian Version:

<https://daneshyari.com/article/5621916>

[Daneshyari.com](https://daneshyari.com)